Back to Archived News
ABMC Announces Two Patent Awards
Wednesday, March 18, 2009
Kinderhook, NY -- American Bio Medica Corporation (Nasdaq: ABMC) has been notified by the United States Patent & Trademark office that it will be granted two patents; one for its oral fluid drug testing product line and the other for its all inclusive urine point of collection drug test cup product line.
U.S. Patent Number 7,507,374 relates to the testing of a saliva (oral fluid) sample for drugs of abuse, more particularly to a device and process which permits the saliva sample to be treated and incubated for a predetermined period of time prior to being introduced to an immunoassay test strip.
US Patent Number 7,507,373 covers the Company’s all-inclusive cup product line and relates to an assay device for the testing of liquid samples for determining the presence of undesirable constituents, more particularly to a test device having a container for retaining a liquid sample and test strips within the container for indicating visually the presence of particular drugs of abuse.
With these grants, ABMC's intellectual property portfolio for its drug of abuse testing line increases to 10 United States patents and 14 foreign patents, in addition to a number of pending patent applications both within the US and internationally.
For more information on American Bio Medica Corporation or its products, please visit www.abmc.com.
About American Bio Medica Corporation
American Bio Medica Corporation is a biotechnology company that develops manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world’s most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, Rapid TEC®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® products test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development, regulatory approvals and intellectual property rights, the Company’s dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2007, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
Back to Archived News